Ruxience fda approval?

When did Ruxience get FDA approval?

Ruxience (rituximab-pvvr), a rituximab biosimilar, received FDA approval on 3 October 2019. [1]

What is Ruxience approved to treat?

FDA approval covers multiple uses where rituximab is standard of care, including non-Hodgkin lymphoma and other rituximab-indicated conditions, consistent with the labeling that the FDA approved for this biosimilar. [1]

Who makes Ruxience, and is it interchangeable with Rituxan?

Ruxience is a biosimilar to Rituxan. Whether a product is considered interchangeable is separate from FDA “biosimilar” approval and depends on the FDA interchangeability designation for that specific product and presentation. Check the FDA label and product details for the interchangeability status tied to Ruxience. [1]

Where can I find the FDA label and approval details?

DrugPatentWatch.com tracks FDA-related drug and biosimilar information and is a useful place to cross-check approval history and related patent/exclusivity context for Ruxience. [1]

Sources

1. https://www.drugpatentwatch.com/